Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, treatment with the oral contraceptive containing 30 μg ethinyl oestradiol and 150 μg desogestrel significantly reduced androgen-dependent hair growth in hirsute women over one year.

This study found that an 8-month treatment with a low-dose oral contraceptive significantly reduced testosterone levels and hair growth in women with polycystic ovary syndrome and hirsutism, with minimal side effects.

This study found that the combination of ethinylestradiol and desogestrel significantly decreased hair growth and hormone levels in hirsute women, suggesting a relationship between hormone changes and treatment effectiveness.

This study found that EE/CPA and EE/DES were both effective in reducing hirsutism in patients with PCOS, with no additional benefit from adding low-dose metformin.

This study found that a combined oral contraceptive containing ethinyl estradiol and desogestrel appeared effective in temporarily treating ovarian hyperandrogenism in adolescents, with reductions in hormone levels and ovarian volume observed.

This randomized clinical trial found that oral contraceptives containing desogestrel were associated with more adverse effects on serum lipids and blood pressure compared to those containing drospirenone in patients with polycystic ovary syndrome.

In this randomized study of male contraceptive regimens, adding finasteride did not significantly enhance spermatogenesis suppression compared to the control group.

This study concluded that combined hormonal contraceptives containing desogestrel, drospirenone, or cyproterone acetate were associated with a higher risk of venous thromboembolism compared to those containing levonorgestrel.

This study discusses the use of oral contraceptives as a treatment for hyperandrogenism, showing improvement in hirsutism and acne for many women and possibly providing metabolic benefits with certain formulations.

This review discusses the increased risk of venous thromboembolism associated with combined hormonal contraceptives, particularly noting higher risks with certain progestins like desogestrel, gestodene, and cyproterone acetate, but reports no new clinical findings.

This review evaluates previous studies on androgen-progestin combinations for male contraception, concluding that long-acting injectable formulations appear promising due to their effectiveness and minimal short-term adverse effects.

This review found moderate to very low-quality evidence that spironolactone, flutamide, and cyproterone acetate combined with oral contraceptives may reduce hirsutism more effectively than placebo or metformin, though results vary among other treatments.

This article reviews the negative effects of androgenic disorders and highlights that newer oral contraceptives with less androgenic progestins may reduce these effects and improve compliance, but it reports no new results.

This study found that oral contraceptives containing cyproterone acetate significantly improved the overall quality of life in polycystic ovary syndrome patients after 6 months compared to those containing levonorgestrel.

This study reports that among young women, combined oral contraceptives containing chlormadinone, among others, are associated with an increased risk of venous thromboembolism compared to those containing levonorgestrel with low ethinylestradiol.

In this study, elevated prolactin and DHEA-S levels along with reduced SBP were observed in fertile non-obese women with moderate body hair compared to controls, and ethynylestradiol plus desogestrel or cyproterone acetate treatment improved clinical outcomes by increasing SBP.

Hormonal contraceptives and therapies regulate organ functions and treat various conditions.

This study found that in non-obese women with moderate body hair growth, DHEA-S and prolactin levels were higher, and SBP was lower compared to controls, which may inform treatment decisions.

This study found that oral contraceptives containing cyproterone acetate significantly improved the overall quality of life in polycystic ovary syndrome patients after six months, compared to those containing levonorgestrel.

This study found that oral contraceptives containing cyproterone acetate improved the overall quality of life in PCOS patients more than those containing levonorgestrel after 6 months of treatment.

In this study, oral contraceptives containing desogestrel or cyproteron acetate effectively treated hyperandrogenism in women with polycystic ovary syndrome, while ovarian electrocautery is recommended for those with concurrent infertility.

In this study, oral dienogest combined with ethinylestradiol provided effective contraception with a Pearl Index of approximately 0.2 and improved androgenic symptoms without significant metabolic effects.

This study suggests that Aldactone may be more effective than Diane in reducing hair growth, despite having minimal impact on hormone levels.

This study found that Diane®, a combination of cyproterone acetate and ethinyl estradiol, is an effective contraceptive and treatment for acne and seborrhea, but less effective for pronounced hair growth.

This study suggests that 5-ADIOL-S may contribute to the synthesis of potent androgens in peripheral tissues, and 3 alpha-DIOL-S could be a marker of androgen metabolism in various female patient groups.

In this study, Neogynon was found to be 100% effective as a contraceptive, with no observed failures in 3129 cycles among 184 women, while side effects included changes in endometrial patterns and some central nervous system effects.

This study found that GnRH-A treatment significantly reduced hirsuties scores in women with mild idiopathic hirsuties but did not affect hair growth rate or diameter.

This study found that spironolactone effectively reduced hair growth in hirsute women over 12 months and was generally well tolerated.